Covered recipient · General Payments record
LAUREN KRAMER
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2023–2024
$992.18
- Reported across 25 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $628.08 | 15 |
| Education | $100.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Arcutis Biotherapeutics, Inc. | $141.08 | 1 |
| GENZYME CORPORATION | $123.79 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $122.07 | 2 |
| Alexion Pharmaceuticals, Inc. | $100.00 | 1 |
| ABBVIE INC. | $78.55 | 3 |
| Lilly USA, LLC | $64.11 | 4 |
| E.R. Squibb & Sons, L.L.C. | $44.05 | 2 |
| Amgen Inc. | $31.38 | 1 |
| Janssen Biotech, Inc. | $23.05 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $26.78 | 01/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107485033 | CMS |
| ABBVIE INC. | $25.10 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107485035 | CMS |
| ABBVIE INC. | $26.67 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107485037 | CMS |
| Alexion Pharmaceuticals, Inc. | $100.00 | 07/23/2024 | Education | Undisputed | 01/23/2026 | 1123306810 | CMS |
| Amgen Inc. | $31.38 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117602401 | CMS |
| Arcutis Biotherapeutics, Inc. | $141.08 | 09/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1121107400 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.96 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101373254 | CMS |
| E.R. Squibb & Sons, L.L.C. | $24.09 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101373264 | CMS |
| GENZYME CORPORATION | $123.79 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139991025 | CMS |
| Janssen Biotech, Inc. | $23.05 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078329921 | CMS |
| Lilly USA, LLC | $17.66 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135783512 | CMS |
| Lilly USA, LLC | $15.89 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135739362 | CMS |
| Lilly USA, LLC | $14.73 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135809371 | CMS |
| Lilly USA, LLC | $15.83 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135790612 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $97.71 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152248936 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $24.36 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152248934 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.